guest ::
| Home > Publications database > Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study. > print |
| Home > Publications database > Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study. > print |
| 001 | 168193 | ||
| 005 | 20240229133600.0 | ||
| 024 | 7 | _ | |a 10.1093/carcin/bgab026 |2 doi |
| 024 | 7 | _ | |a pmid:33780524 |2 pmid |
| 024 | 7 | _ | |a 0143-3334 |2 ISSN |
| 024 | 7 | _ | |a 1460-2180 |2 ISSN |
| 024 | 7 | _ | |a altmetric:102978172 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-00733 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Aglago, Elom K |b 0 |
| 245 | _ | _ | |a Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study. |
| 260 | _ | _ | |a Oxford |c 2021 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1626273545_24480 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 May 28;42(5):705-713 |
| 520 | _ | _ | |a Advanced glycation end-products (AGEs) are a heterogeneous group of compounds formed by the non-enzymatic reaction between amino-acids and reducing sugars, or dicarbonyls as intermediate compounds. Experimental studies suggest that AGEs may promote colorectal cancer, but prospective epidemiologic studies are inconclusive. We conducted a case-control study nested within a large European cohort. Plasma concentrations of three protein-bound AGEs: N ε-(carboxy-methyl)lysine (CML), N ε-(carboxy-ethyl)lysine (CEL) and N δ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) were measured by ultra-performance liquid chromatography tandem mass-spectrometry in baseline samples collected from 1,378 incident primary colorectal cancer cases and 1,378 matched controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional logistic regression for colorectal cancer risk associated with CML, CEL, MG-H1, total AGEs, and [CEL+MG-H1: CML] and [CEL:MG-H1] ratios. Inverse colorectal cancer risk associations were observed for CML (OR comparing highest to lowest quintile, ORQ5vs.Q1=0.40, 95%CI:0.27-0.59), MG-H1 (ORQ5vs.Q1=0.73, 95%CI:0.53 - 1.00) and total AGEs (OR Q5vs.Q1=0.52, 95%CI:0.37 - 0.73) whereas no association was observed for CEL. A higher [CEL+MG-H1: CML] ratio was associated with colorectal cancer risk (ORQ5vs.Q1=1.91, 95%CI:1.31-2.79). The associations observed did not differ by sex, or by tumour anatomical subsite. Although individual AGEs concentrations appear to be inversely associated with colorectal cancer risk, a higher ratio of methylglyoxal-derived AGEs versus those derived from glyoxal (calculated by [CEL+MG-H1: CML] ratio) showed a strong positive risk association. Further insight on the metabolism of AGEs and their dicarbonyls precursors, and their roles in colorectal cancer development is needed. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |x 0 |f POF IV |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Advanced glycation end-product |2 Other |
| 650 | _ | 7 | |a colorectal cancer |2 Other |
| 650 | _ | 7 | |a glycotoxin |2 Other |
| 700 | 1 | _ | |a Schalkwijk, Casper G |b 1 |
| 700 | 1 | _ | |a Freisling, Heinz |b 2 |
| 700 | 1 | _ | |a Fedirko, Veronika |b 3 |
| 700 | 1 | _ | |a Hughes, David J |b 4 |
| 700 | 1 | _ | |a Jiao, Li |b 5 |
| 700 | 1 | _ | |a Dahm, Christina C |b 6 |
| 700 | 1 | _ | |a Olsen, Anja |b 7 |
| 700 | 1 | _ | |a Tjønneland, Anne |b 8 |
| 700 | 1 | _ | |a Katzke, Verena |0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |b 9 |u dkfz |
| 700 | 1 | _ | |a Johnson, Theron |0 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa |b 10 |u dkfz |
| 700 | 1 | _ | |a Schulze, Matthias B |b 11 |
| 700 | 1 | _ | |a Aleksandrova, Krasimira |b 12 |
| 700 | 1 | _ | |a Masala, Giovanna |b 13 |
| 700 | 1 | _ | |a Sieri, Sabina |b 14 |
| 700 | 1 | _ | |a Simeon, Vittorio |b 15 |
| 700 | 1 | _ | |a Tumino, Rosario |b 16 |
| 700 | 1 | _ | |a Macciotta, Alessandra |b 17 |
| 700 | 1 | _ | |a Bueno-de-Mesquita, Bas |b 18 |
| 700 | 1 | _ | |a Skeie, Guri |b 19 |
| 700 | 1 | _ | |a Gram, Inger Torhild |b 20 |
| 700 | 1 | _ | |a Sandanger, Torkjel |b 21 |
| 700 | 1 | _ | |a Jakszyn, Paula |b 22 |
| 700 | 1 | _ | |a Sánchez, Maria-Jose |b 23 |
| 700 | 1 | _ | |a Amiano, Pilar |b 24 |
| 700 | 1 | _ | |a Colorado-Yohar, Sandra M |b 25 |
| 700 | 1 | _ | |a Gurrea, Aurelio Barricarte |b 26 |
| 700 | 1 | _ | |a Perez-Cornago, Aurora |b 27 |
| 700 | 1 | _ | |a Mayén, Ana-Lucia |b 28 |
| 700 | 1 | _ | |a Weiderpass, Elisabete |b 29 |
| 700 | 1 | _ | |a Gunter, Marc J |b 30 |
| 700 | 1 | _ | |a Heath, Alicia K |b 31 |
| 700 | 1 | _ | |a Jenab, Mazda |b 32 |
| 773 | _ | _ | |a 10.1093/carcin/bgab026 |g p. bgab026 |0 PERI:(DE-600)1474206-8 |n 5 |p 705-713 |t Carcinogenesis |v 42 |y 2021 |x 1460-2180 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:168193 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Cancer risk factors and prevention |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-02-04 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CARCINOGENESIS : 2019 |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-02-04 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-04 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-02-04 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|